Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxaneยฎ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
- Conditions
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00016341
- Locations
- ๐บ๐ธ
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
๐บ๐ธRush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
๐บ๐ธArthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
- Conditions
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00016874
- Locations
- ๐บ๐ธ
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
๐บ๐ธNew York Presbyterian Hospital - Cornell Campus, New York, New York, United States
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-04
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 396
- Registration Number
- NCT00016276
- Locations
- ๐บ๐ธ
Cancer and Leukemia Group B, Chicago, Illinois, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-25
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 12
- Registration Number
- NCT00004221
- Locations
- ๐บ๐ธ
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
- Conditions
- First Posted Date
- 2003-08-25
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00004125
- Locations
- ๐บ๐ธ
State University of New York - Upstate Medical University, Syracuse, New York, United States
๐บ๐ธCCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States
๐บ๐ธCCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2009-12-08
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 39
- Registration Number
- NCT00066716
- Locations
- ๐บ๐ธ
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- Theradex
- Registration Number
- NCT00025688
- Locations
- ๐บ๐ธ
Scott and White Clinic, Temple, Texas, United States
๐บ๐ธMaryland Hematology/Oncology Associates, Baltimore, Maryland, United States
๐บ๐ธOncology Consultants, Houston, Texas, United States
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2003-07-25
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 774
- Registration Number
- NCT00006229
- Locations
- ๐จ๐ฆ
CancerCare Manitoba, Winnipeg, Manitoba, Canada
๐ฆ๐นAKH Vienna, Vienna (Wien), Austria
๐บ๐ธMemorial Hospital Cancer Center - Chattanooga, Chattanooga, Tennessee, United States
Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
- Conditions
- First Posted Date
- 2003-07-24
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- The Christie NHS Foundation Trust
- Registration Number
- NCT00004887
- Locations
- ๐ฌ๐ง
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
- Conditions
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Baptist Health South Florida
- Registration Number
- NCT00004253
- Locations
- ๐บ๐ธ
Baptist Hospital of Miami, Miami, Florida, United States
๐บ๐ธSylvester Cancer Center, University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.